PPP5C Antibody

What is PPP5C and why is it significant in research?

PPP5C (protein phosphatase 5, catalytic subunit) is a serine/threonine protein phosphatase that exhibits a unique dual function by simultaneously performing dephosphorylation activities and co-chaperone functions . This 57 kDa protein (499 amino acids) participates in numerous cellular signaling pathways, including MAPK signaling, DNA damage repair, and stress response mechanisms . PPP5C has been found to regulate proteins involved in cell cycle progression, apoptosis, and hormone responses, making it a critical target in cancer research, particularly in prostate, pancreatic, and other malignancies .

The significance of PPP5C lies in its involvement in:

• Modulation of JNK and ERK phosphorylation pathways

• DNA damage repair via interaction with DNA-dependent protein kinase catalytic subunit

• Cell cycle regulation, particularly at the G0/G1 phase transition

• Tumor development and progression in various cancers

How do I select the appropriate PPP5C antibody for my research application?

Selection of a PPP5C antibody should be guided by:

Application compatibility:

Immunogen and epitope: For studying specific domains or detecting particular isoforms, select antibodies raised against the relevant region. Some antibodies are generated against full-length recombinant PPP5C protein, while others target specific peptide sequences .

Validation data: Review available validation data, including published applications and positive control expression data in relevant cell lines (e.g., HEK-293, HeLa, K-562) .

What are the optimal conditions for using PPP5C antibodies in Western blotting?

Recommended protocol for PPP5C detection by Western blot:

• Sample preparation:

  • For cell lines: Wash cells twice with ice-cold PBS and homogenize in cell lysis buffer

  • For tissue samples: Homogenize in appropriate extraction buffer containing protease inhibitors

  • Use 20-50 μg of total protein per lane

• Gel electrophoresis and transfer:

  • Use 8-12% SDS-PAGE gels for optimal separation of PPP5C (57 kDa)

  • Transfer to PVDF or nitrocellulose membrane at 100V for 60-90 minutes

• Blocking and antibody incubation:

  • Block membrane with 5% non-fat milk or 2-5% BSA in TBST for 1 hour at room temperature

  • Dilute primary antibody in TBST containing 2% BSA at recommended dilution (typically 1:500-1:2000)

  • Incubate with primary antibody for 18 hours at 4°C

  • Wash membrane 3-5 times with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (typically 1:2000-1:5000)

• Detection:

  • Visualize using ECL Western blotting detection reagents

  • Expected molecular weight of PPP5C is approximately 57 kDa

• Controls:

  • Positive controls: HEK-293, HeLa, and K-562 cell lysates have been validated for PPP5C expression

  • Negative control: Consider using PPP5C knockdown samples when available

How can I optimize PPP5C antibody use in immunohistochemistry?

Optimized IHC protocol for PPP5C detection:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-6 μm thickness

• Antigen retrieval options:

  • Primary recommendation: Use TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval methods (pressure cooker, microwave) typically yield better results

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum

  • Dilute primary antibody at 1:50-1:500 in antibody diluent

  • Incubate primary antibody at 4°C overnight or at room temperature for 1-2 hours

  • Apply appropriate secondary antibody and detection system

• Controls and validation:

  • Positive control: Human gliomas tissue has shown reliable PPP5C expression

  • For cancer studies, compare expression between tumor and adjacent normal tissue

  • PPP5C shows differential expression between cancer and normal tissues in various malignancies, with often higher expression in tumor samples

• Optimization note:

  • Antibody titration is strongly recommended for each testing system to obtain optimal results

  • Some tissues may require specific modifications to the protocol

How can PPP5C antibodies be utilized in cancer research, particularly for studying its role in tumorigenesis?

PPP5C has emerged as a significant player in cancer biology with its overexpression documented in multiple malignancies. Researchers can utilize PPP5C antibodies in several advanced applications:

Expression profiling in clinical samples:

• IHC analysis of PPP5C in tumor and matched normal tissues has revealed significant overexpression in prostate cancer , pancreatic cancer , and other malignancies

• In prostate cancer studies, PPP5C staining was deeper and wider in tumor tissues compared to adjacent normal tissues, with 63.5% of tumor samples showing positive or strongly positive staining versus only 19.2% in adjacent tissue

• PPP5C expression appears even higher in metastatic tissues compared to primary prostate cancer lesions

Functional studies:

• Combine PPP5C antibodies with knockdown experiments to validate specificity and correlate expression with functional outcomes

• Studies using lentivirus-mediated shRNA to silence PPP5C have demonstrated inhibition of cell proliferation and colony formation in multiple cancer cell lines

• Flow cytometry analysis after PPP5C knockdown revealed G0/G1 cell cycle arrest and increased apoptosis in prostate cancer cell lines (DU145, PC3, 22RV1)

Signaling pathway analysis:

• Western blot analyses using phospho-specific antibodies have shown that PPP5C knockdown augments JNK and ERK1/2 phosphorylation , suggesting a regulatory role in these pathways

• PPP5C antibodies can be used alongside phospho-specific antibodies to monitor how PPP5C regulates downstream targets in response to therapeutic agents

• In pancreatic cancer cells, PPP5C silencing combined with gemcitabine treatment significantly increased apoptosis through enhanced JNK phosphorylation

Biomarker potential:

• Multiple studies suggest PPP5C may serve as a diagnostic biomarker and therapeutic target

• Researchers can use PPP5C antibodies in multiplex IHC/IF to study co-expression with other cancer markers for improved diagnostic accuracy

What approaches can be used to study the dual function of PPP5C as both a phosphatase and co-chaperone?

Studying the dual functionality of PPP5C requires sophisticated experimental approaches:

Protein-protein interaction studies:

• Immunoprecipitation using PPP5C antibodies followed by mass spectrometry to identify interacting partners

• Co-immunoprecipitation studies to confirm specific interactions with chaperone proteins and phosphorylation substrates

• Pull-down assays using tagged PPP5C to distinguish between phosphatase substrates and chaperone clients

Structural and functional domain analysis:

• Use different PPP5C antibodies targeting specific domains to distinguish between phosphatase and co-chaperone functions

• Apply domain-specific blocking peptides alongside PPP5C antibodies to selectively inhibit one function while preserving the other

• Combine with site-directed mutagenesis studies to correlate structure with function

Phosphatase activity assays:

• In vitro phosphatase assays using immunoprecipitated PPP5C to measure enzymatic activity

• Compare wild-type PPP5C with phosphatase-dead mutants to distinguish phosphatase-dependent and -independent functions

• Use phospho-specific antibodies against known PPP5C substrates (e.g., JNK, ERK) to monitor dephosphorylation events in cellular contexts

Co-chaperone function analysis:

• Examine PPP5C's interaction with heat shock proteins using antibodies against both proteins

• Study the effects of stress conditions on PPP5C localization and interactions using immunofluorescence and co-IP approaches

• Investigate PPP5C's role in protein folding and stability of client proteins in various cellular contexts

What are common challenges when using PPP5C antibodies and how can they be addressed?

Challenge 1: Nonspecific binding and background signals

• Solution: Optimize blocking conditions using 3-5% BSA or 5% milk in TBST. Consider increasing washing steps (5x5 minutes with TBST).

• For IHC applications, use antigen retrieval with TE buffer pH 9.0 as primary recommendation, or alternatively try citrate buffer pH 6.0 .

• Titrate antibody concentration carefully for each application (WB: 1:500-1:2000; IHC: 1:50-1:500) .

Challenge 2: Inconsistent detection across different tissues or cell lines

• Solution: Verify PPP5C expression levels in your experimental system. Positive controls include HEK-293, HeLa, and K-562 cells for Western blot .

• For IHC, human gliomas tissue has been validated for PPP5C expression .

• Consider species-specific differences in PPP5C sequence and confirm antibody cross-reactivity for your model organism.

Challenge 3: Difficulty detecting endogenous PPP5C due to low expression

• Solution: Increase protein loading (50-100 μg per lane) for Western blot.

• Use enhanced chemiluminescence (ECL) detection systems with higher sensitivity.

• Consider enrichment by immunoprecipitation before Western blot analysis.

• For IHC, extend primary antibody incubation time (overnight at 4°C) and optimize antigen retrieval methods.

Challenge 4: Multiple bands in Western blot

• Solution: Verify expected molecular weight (57 kDa for full-length PPP5C) .

• Additional bands might represent post-translational modifications, degradation products, or non-specific binding.

• Include positive and negative controls (PPP5C knockdown samples) to confirm specificity .

• Test multiple antibody clones if available to confirm consistent detection patterns.

How can researchers validate PPP5C antibody specificity for their experimental system?

Multiple validation approaches are recommended:

• Genetic validation:

  • Use PPP5C knockdown or knockout samples as negative controls

  • Studies have successfully employed lentivirus-mediated shRNA targeting PPP5C in cancer cell lines

  • The observed phenotypes (decreased proliferation, G0/G1 arrest, increased apoptosis) provide functional validation

• Peptide competition assay:

  • Pre-incubate PPP5C antibody with excess immunizing peptide before application

  • Specific signals should be significantly reduced or eliminated

  • Non-specific signals will remain largely unchanged

• Multiple antibody validation:

  • Compare results using different antibody clones targeting distinct epitopes

  • Monoclonal antibodies like OTI2E12 and OTI6C2 can be compared with polyclonal antibodies

  • Concordant results across multiple antibodies increase confidence in specificity

• Recombinant protein expression:

  • Express tagged recombinant PPP5C and confirm detection with both tag-specific and PPP5C-specific antibodies

  • This approach can validate antibody recognition of the target protein in a controlled system

• Mass spectrometry validation:

  • Perform immunoprecipitation using the PPP5C antibody followed by mass spectrometry

  • Confirm that PPP5C is among the identified proteins

  • This approach provides independent verification of antibody specificity

How can PPP5C antibodies be used to study its role in chemoresistance mechanisms?

Recent studies have implicated PPP5C in chemoresistance, particularly in pancreatic cancer. Researchers can utilize PPP5C antibodies to:

Monitor expression changes during treatment:

• Western blot analysis revealed increased PPP5C expression in PANC-1 cells treated with gemcitabine (GEM)

• Track PPP5C levels before, during, and after chemotherapy treatment in various cancer cell lines

Study combination therapies:

• PPP5C knockdown in combination with gemcitabine treatment significantly enhanced cell death compared to either intervention alone

• Use PPP5C antibodies to monitor protein levels and pathway activation (JNK, ERK) when testing novel therapeutic combinations

Mechanistic studies:

• Western blot analysis using PPP5C and phospho-specific antibodies showed that PPP5C silencing significantly increased the protein levels of cleaved caspase-3, p-p53, and cleaved-PARP in chemotherapy-treated cells

• The combination of PPP5C silencing and gemcitabine treatment markedly increased p-JNK/JNK ratios

• These findings suggest that PPP5C inhibition may enhance chemotherapy efficacy by promoting apoptotic signaling

Patient-derived samples:

• Compare PPP5C expression in chemotherapy-resistant versus sensitive patient samples

• Correlate expression with treatment outcomes and survival data

• Consider PPP5C as a potential predictive biomarker for chemotherapy response

What approaches can be used to study PPP5C's role in DNA damage response pathways?

PPP5C has been implicated in DNA damage repair mechanisms through its interactions with key proteins. Researchers can investigate this role using:

Co-localization studies:

• Immunofluorescence with PPP5C antibodies combined with markers of DNA damage repair foci (γH2AX, 53BP1)

• Track PPP5C localization before and after DNA-damaging treatments (UV, radiation, chemotherapy)

Pathway analysis:

• Western blot analysis of PPP5C and its potential substrates in the DNA damage response pathway

• PPP5C has been shown to interact with DNA-dependent protein kinase catalytic subunit, ataxia telangiectasia mutated, ATM- and RAD3-related, and p53

• Study how PPP5C affects the phosphorylation status of these proteins following DNA damage

Functional assays:

• Use PPP5C antibodies to validate knockdown efficiency when studying DNA repair capacity

• Combine with assays measuring double-strand break repair, nucleotide excision repair, or other DNA repair pathways

• Compare repair kinetics in PPP5C-depleted versus control cells

Chromatin association:

• Perform chromatin immunoprecipitation followed by sequencing (ChIP-seq) using PPP5C antibodies

• Investigate whether PPP5C is recruited to sites of DNA damage

• Analyze temporal dynamics of recruitment and dissociation during the repair process

How might PPP5C antibodies facilitate the development of targeted therapies?

The emerging role of PPP5C as a potential therapeutic target creates opportunities for antibody-based research:

Target validation studies:

• Use PPP5C antibodies to confirm target engagement in preclinical models

• Monitor changes in PPP5C expression, localization, and activity in response to candidate compounds

• Studies have already shown that disruption of PPP5C inhibits tumorigenesis in bladder cancer and enhances chemosensitivity in pancreatic cancer

Drug discovery platforms:

• Develop high-throughput screening assays using PPP5C antibodies to identify compounds that modulate PPP5C activity or expression

• Focus on compounds that could overcome the challenges of targeting PPP5C due to its "special monomeric enzyme form and low basal activity by a self-inhibition mechanism"

Combination therapy development:

• Study PPP5C expression and pathway activation in response to standard therapies

• Identify synergistic combinations that target PPP5C-regulated pathways

• PPP5C silencing combined with gemcitabine treatment has shown promising results in pancreatic cancer models

Biomarker development:

• Validate PPP5C as a predictive biomarker for treatment response

• Standardize PPP5C antibody-based assays for potential clinical application

• Correlate PPP5C expression levels with patient outcomes to identify subgroups that might benefit from targeted therapies

What are emerging methods for studying the interplay between PPP5C and other signaling pathways?

As understanding of PPP5C's role in cellular signaling expands, novel methodological approaches are being developed:

Proximity-based protein interaction assays:

• BioID or APEX2 proximity labeling using PPP5C fusion proteins

• Identify proteins in close proximity to PPP5C under various conditions

• Validate interactions using conventional co-IP with PPP5C antibodies

Phosphoproteomics analysis:

• Compare phosphoproteomes in PPP5C-knockdown versus control cells

• Identify direct and indirect phosphorylation targets

• Focus on pathways already implicated in PPP5C function, such as MAPK, JNK, and p53

Single-cell analysis:

• Apply single-cell Western blot or mass cytometry techniques with PPP5C antibodies

• Investigate cell-to-cell variability in PPP5C expression and activity

• Correlate with cell state, cell cycle phase, or response to treatment

CRISPR-based approaches:

• Combine CRISPR screens with PPP5C antibody-based readouts to identify genetic modifiers of PPP5C function

• Use CRISPR activation or inhibition of PPP5C in combination with pathway analysis

• Validate findings using traditional biochemical approaches with PPP5C antibodies

Mathematical modeling:

• Integrate quantitative PPP5C expression data with signaling pathway dynamics

• Develop predictive models of PPP5C's role in cellular decision-making

• Test model predictions experimentally using PPP5C antibodies and pathway-specific readouts